A laboratory of the vaccine company Bavarian Nordic

[shoponhossaiassn]

Jynneos is so new that the CDC only published its formal recommendations for use of the vaccine in the agency's Morbidity and Mortality Weekly Report on Friday, following a months-long deliberation among its outside vaccine advisers.

"Today's MMWR comes at an opportune time, with the current increase in monkeypox cases internationally; however, the new guidelines were not created in response to the monkeypox outbreak," the CDC said in a statement.

Previously, the U.S. had only had one vaccine available to head off orthopoxviruses, called ACAM2000. Jynneos has several advantages over ACAM2000, including lower risks of bad side effects and easier administration.

"CDC experts have been working to refine usage recommendations buy phone number list during the past two years," the agency's statement said, adding that the guidance was unanimously approved by its advisory panel late last year.

Supply of the vaccine
It is unclear exactly how many doses of Jynneos will be available for use in the U.S. if the outbreak swells.

Bavarian Nordic, which credits the U.S. government for pouring millions of dollars into the company's development of the vaccine, claimed earlier this month to investors that it had "supplied nearly 30 million doses" of a liquid-frozen version of its vaccine for the federal Strategic National Stockpile to date.

However, the company had acknowledged in 2019 it was in the process of working "to replenish and potentially expand the stockpile, which has expired" with a different "freeze-dried" formulation of the vaccine.

FILE PHOTO:
An employee in a lab of the vaccine company Bavarian Nordic in Martinsried, near Munich, Germany, May 24, 2022.
LUKAS BARTH / REUTERS
"Right now, we have over a thousand doses of that available, and we expect that level to ramp up very quickly in the coming weeks as the company provides more doses to us," the CDC's Jennifer McQuiston told reporters on Monday.